What is the catalog number for Valemetostat?

The catalog number for Valemetostat is HY-109108.

What sizes are available for Valemetostat?

Valemetostat is available in the following size(s): 1 mg, 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Valemetostat come in?

Valemetostat is available in 7 different pack sizes.

Is Valemetostat in stock?

Valemetostat is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Valemetostat?

Valemetostat is manufactured by QuantiMol.

What is the estimated delivery time for Valemetostat?

Estimated delivery time for Valemetostat is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Valemetostat?

The safety data sheet for Valemetostat is available here: http://file.medchemexpress.com/batch_PDF/HY-109108/Valemetostat-SDS-MedChemExpress.pdf.

Valemetostat

Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC50 values [1][2][3].

Product Specifications

CAS Number

1809336-39-7

Product Name Alternative

DS-3201

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Valemetostat.html

Purity

99.84

Solubility

DMSO : 70 mg/mL (ultrasonic)

Smiles

CC1=C(O[C@@](C)([C@]2([H])CC[C@@H](N(C)C)CC2)O3)C3=C(Cl)C=C1C(NCC(C4=O)=C(C=C(C)N4)C)=O

Molecular Formula

C26H34ClN3O4

Molecular Weight

488.02

Precautions

H302, H315, H319, H335

References & Citations

[1]Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW.|[2]Shimizu J, Kawano F. Exercise-induced histone H3 trimethylation at lysine 27 facilitates the adaptation of skeletal muscle to exercise in mice. J Physiol. 2022 Jul;600 (14) :3331-3353.|[3]Yamagishi M, et al. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. Cell Rep. 2019 Nov 19;29 (8) :2321-2337.e7.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

EZH1

Citation 01

Cancer Res. 2025 May 15;85 (10) :1803-1818.|Cells. 2023 Dec 30;13 (1) :81.|Am J Pathol. 2025 Jun;195 (6) :1124-1140.|Protein Cell. 2025 Jun 20;16 (6) :439-457.